GMAB vs. ALNY, HZNP, BGNE, BMRN, VTRS, RDY, UTHR, LEGN, SRPT, and VRNA
Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals received 941 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.08% of users gave Alnylam Pharmaceuticals an outperform vote while only 59.24% of users gave Genmab A/S an outperform vote.
In the previous week, Genmab A/S had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 7 mentions for Genmab A/S and 6 mentions for Alnylam Pharmaceuticals. Genmab A/S's average media sentiment score of 1.39 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Alnylam Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
94.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 6.3% of Genmab A/S shares are held by institutional investors. 1.4% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Genmab A/S has a net margin of 28.78% compared to Genmab A/S's net margin of -85.95%. Alnylam Pharmaceuticals' return on equity of 16.93% beat Genmab A/S's return on equity.
Alnylam Pharmaceuticals currently has a consensus price target of $245.52, indicating a potential upside of 41.08%. Genmab A/S has a consensus price target of $756.80, indicating a potential upside of 2,042.09%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.
Summary
Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Genmab A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Genmab A/S Competitors List
Related Companies and Tools